Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurotrophic factor producing mesenchymal stem cell derived exosome therapeutics - Brainstorm Cell Therapeutics

Next Previous
Drug Profile

Research programme: neurotrophic factor producing mesenchymal stem cell derived exosome therapeutics - Brainstorm Cell Therapeutics

Alternative Names: MSC-NTF (NurOwn®) Exosomes; MSC-NTF exosomes; NurOwn (MSC-NTF) exosomes; NurOwn® derived exosomes

Latest Information Update: 10 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brainstorm Cell Therapeutics
  • Class Exosome therapies
  • Mechanism of Action Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 03 Dec 2024 BrainStorm Cell Therapeutics receives a Notice of Allowance for patent protection on its exosome technology in USA
  • 28 Aug 2024 No recent reports of development identified for preclinical development in SARS-COV-2 acute respiratory disease in Israel (Intratracheal)
  • 21 Jan 2021 Pharmacodynamics data from preclinical studies in SARS-COV-2 acute respiratory disease released by Brainstorm Cell Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top